Identification of prognostic genes in uveal melanoma microenvironment by Luo, Huan & Ma, Chao
RESEARCH ARTICLE
Identification of prognostic genes in uveal
melanoma microenvironment
Huan Luo1,2☯, Chao Ma1,3☯*
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Uveal melanoma (UM) is the most common primary intraocular malignancy in adults. Many
previous studies have demonstrated that the infiltrating of immune and stromal cells in the
tumor microenvironment contributes significantly to prognosis.
Methods
Dataset TCGA-UVM, download from TCGA portal, was taken as the training cohort, and
GSE22138, obtained from GEO database, was set as the validation cohort. ESTIMATE
algorithm was applied to find intersection differentially expressed genes (DEGs) among
tumor microenvironment. Kaplan-Meier analysis and univariate Cox regression model were
performed on intersection DEGs to initial screen for potential prognostic genes. Then these
genes entered into the validation cohort for validation using the same methods as that in the
training cohort. Moreover, we conducted correlation analyses between the genes obtained
in the validation cohort and the status of chromosome 3, chromosome 8q, and tumor metas-
tasis to get prognosis genes. At last, the immune infiltration analysis was performed
between the prognostic genes and 6 main kinds of tumor-infiltrating immune cells (TICs) for
understanding the role of the genes in the tumor microenvironment.
Results
959 intersection DEGs were found in the UM microenvironment. Kaplan-Meier and Cox
analysis was then performed in the training and validation cohorts on these DEGs, and 52
genes were identified with potential prognostic value. After comparing the 52 genes to chro-
mosome 3, chromosome 8q, and metastasis, we obtained 21 genes as the prognostic
genes. The immune infiltration analysis showed that Neutrophil had the potential prognostic
ability, and almost every prognostic gene we had identified was correlated with abundances
of Neutrophil and CD8+ T Cell.
PLOS ONE







Citation: Luo H, Ma C (2020) Identification of
prognostic genes in uveal melanoma
microenvironment. PLoS ONE 15(11): e0242263.
https://doi.org/10.1371/journal.pone.0242263
Editor: Nikolas K. Haass, University of Queensland
Diamantina Institute, AUSTRALIA
Received: February 24, 2020
Accepted: October 30, 2020
Published: November 16, 2020
Copyright: © 2020 Luo, Ma. This is an open access
article distributed under the terms of the Creative
Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in
any medium, provided the original author and
source are credited.
Data Availability Statement: Publicly available
datasets were analyzed in this study. These data
can be found here: TCGA: https://portal.gdc.cancer.
gov/projects/TCGA-UVM; GEO: https://www.ncbi.
nlm.nih.gov/geo/query/acc.cgi?acc=GSE22138.
Funding: Huan Luo and Chao Ma received support
from Zhengzhou University Overseas Virtual
Research Institute for pursuing doctorates in
Germany. Chao Ma received funding from the
China Scholarship Council (No. 201708410121) for
studying in Germany. We acknowledge support
from the German Research Foundation (DFG) and
the Open Access Publication Fund of Charité –
Conclusions
Identifying 21 prognosis genes (SERPINB9, EDNRB, RAPGEF3, HFE, RNF43, ZNF415,
IL12RB2, MTUS1, NEDD9, ZNF667, AZGP1, WARS, GEM, RAB31, CALHM2, CA12,
MYEOV, CELF2, SLCO5A1, ISM1, and PAPSS2) could accurately identify patients’ prog-
nosis and had close interactions with Neutrophil in the tumor environment, which may pro-
vide UM patients with personalized prognosis prediction and new treatment insights.
Introduction
Uveal melanoma (UM) accounts for 3% -5% of all melanomas and is the most common pri-
mary intraocular malignancy in adults. UM comprises approximately 95 percent of melano-
mas from the eye, with the remainder arising from the conjunctiva [1]. UM usually appears
asymptomatic and is found during routine eye examinations. About half of patients will
develop visual symptoms such as flashing, floating objects, or visual field defects [2]. About
20% to 30% of patients diagnosed with primary UM die from systemic metastases within five
years of diagnosis, and 45% die within 15 years of initial diagnosis [3]. American Cancer Soci-
ety reported that when UM was spread to distant parts of the body, the 5-year relative survival
rate was about 13% [4]. The median age at diagnosis is about 62 years, but the peak of the diag-
nosis ranges from 70 to 79 years [5]. No therapy has been shown to improve overall survival
for patients with UM [5]. Further understanding of the molecular pathogenesis of UM can
provide vital information for exploring prognostic factors [5].
The tumor microenvironment is the environment surrounding the tumor, including sur-
rounding blood vessels, immune cells, fibroblasts, signaling molecules, and extracellular
matrix [6]. The tumor is closely related to the surrounding microenvironment and continu-
ously interacts and together promotes the tumor’s immune escape, growth, and metastasis,
which all reflect the evolutionary nature of the tumor [6, 7]. It is reported that the level of
immune cell infiltration is related to the prognosis. The activity of immune cells and stromal
cells has been shown to predict the overall survival of cancer [8]. The inflammatory phenotype
of UM is characterized by high infiltration of lymphocytes and macrophages and by the
expression of human leukocyte antigen (HLA) Class I and II antigens [9]. Narasimhaiah and
colleagues found that UM with IFNγ-signature had a poorer prognosis and showed increased
infiltration of CD8+ T lymphocytes and macrophages. In UM, it was demonstrated that
immune cell infiltration was associated with poorer outcomes in the intermediate-risk group
and increased in high-risk group (73.7%) [10]. ESTIMATE, designed by Yoshihara et al., is a
tool for predicting tumor purity, and the presence of infiltrating stromal/immune cells in
tumor tissues using gene expression data [11]. Based on the ESTIMATE algorithm, the
researchers obtained more possibilities to evaluate and explore the genetic changes of malig-
nant tumors [12–14]. However, the distribution of immune and stromal scores in UM, and
whether the ESTIMATE algorithm can be used to investigate the prognosis of patients with
UM remains elucidated.
During the past few decades, genetic or epigenetic alterations have been confirmed to be
associated with the tumorigenesis and progression of UM [15]. Gene mutations and chromo-
somal copy number variations are closely related to UM prognosis. According to reports,
GNAQ and GNA11 mutations can promote cell proliferation and metastasis [16]. The loss of
one copy of chromosome 3 (monosomy 3) in UM is associated with an increased risk of metas-
tasis and poor prognosis [17]. Other chromosomal abnormalities have been shown to correlate
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with poor prognosis, including 8q gain, 6q loss, lack of 6p gain, 1p loss, and 16q loss [17–21].
Therefore, further exploration of gene mutation and copy number variation in UM can pro-
vide incisive information for prognosis.
To better understand the molecular pathogenesis of UM, in the present study, we used the
ESTIMATE algorithm in conjunction with TCGA and GEO databases, along with the compar-
ison with the status of chromosomal copy number variations to discover potential markers in
the UM microenvironment.
Materials and methods
Data mining from TCGA and GEO
The gene expression profiles of UM from 80 patients and their clinical and survival data were
downloaded from TCGA Xena Hub (https://tcga.xenahubs.net) with cohort name: TCGA
Ocular melanomas (TCGA-UVM). Also, we researched the GEO database (https://www.ncbi.
nlm.nih.gov/geo/) by setting a filter: 1) more than 60 cases; 2) with expression profiling data;
3) with survival data. At last, we selected dataset GSE22138, which contains 63 UM cases, for
the study. In our research, TCGA-UVM was used as training cohort, while GSE22138 was
taken as validation cohort.
Immune and stromal scores
Immune scores and stromal scores of each case of the training cohort were calculated by the
ESTIMATE algorithm R package named "ESTIMATE" (https://bioinformatics.mdanderson.
org/public-software/estimate/, S1 Table) [11].
Identification of the intersection differentially expressed genes (DEGs)
among immune and stromal scores
According to their scores based on the median, all training cohort cases were divided into
groups of high and low scores. DEGs were identified between high and low immune/stromal
score groups using "limma" R package [22], with a cutoff of |log2(fold-change) |> 1 and false
discovery rate (FDR) < 0.05. "pheatmap" R package was applied to produce heatmaps and
clustering of DEGs. Genes that were up-regulated in both high immune and stromal scores
groups were defined as intersection-up-regulated DEGs. Genes that were down-regulated in
both high immune and stromal scores groups were taken as intersection-down-regulated
DEGs. A combination of these two intersection DEGs was the intersection DEGs. Besides, the
Metascape web tool (https://metascape.org/) was applied to perform Gene Ontology (GO) and
Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis on the intersection
DEGs [23].
Identification and validation of the potential prognostic genes
In the training cohort, Kaplan-Meier analysis was used to screen for potential prognostic
genes from the intersection DEGs identified in the previous step based on overall survival.
Only genes with p-value < 0.01 in the log-rank test were considered significant to pass
Kaplan-Meier analysis screening. Also, univariate Cox regression analysis was performed on
the training cohort to look for prognostic genes from the intersection DEGs with p-
value < 0.01. Same as before, only genes that showed significant in the overall survival analysis
were considered to pass univariate Cox regression analysis screening. The genes passed both
Kaplan-Meier and univariate Cox analyses in the training cohort were then entered into the
validation cohort for validation. The same methods were conducted like that in the training
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cohort. Only genes both passed the Kaplan–Meier and univariate Cox analyses with the cutoff
p-value < 0.001 were able to move to the next step.
Screen prognostic genes based on correlation with chromosome 3,
chromosome 8q, and metastasis
In UM, chromosomal aberrations and gene mutations are closely related to treatment options
and prognosis [17]. Moreover, metastasis is a strong predictor of the adverse outcome. Only a
fraction of patients with UM metastasis survive, and almost all metastases die [24]. In Robert-
son’s research, the status of chromosome 3 and 8q of each patient in the TCGA-UVM cohort
has been studied and specifically described [17]. The Spearman rank correlation coefficient
was applied to assess the correlations between the expression of each potential prognostic gene
identified in the previous step and the copy number aberrations, as well as the metastasis sta-
tus. Only genes passed all the correlation tests were taken as prognostic genes. P-value < 0.05
was considered statistically significant.
Correlation of prognostic genes with the abundances of six kinds of tumor-
infiltrating immune cells (TICs)
TIMER web server [25, 26] (https://cistrome.shinyapps.io/timer/) is a comprehensive resource
for systematical analysis of immune infiltrates across diverse cancer types. The abundances of
six immune infiltrates (B cells, CD4+ T cells, CD8+ T cells, Neutrophils, Macrophages, and
Dendritic cells) are estimated by TIMER algorithm. The TIMER web server was applied to
estimate the correlations between the abundances of TICs and the prognosis of UM via meth-
ods of Kaplan-Meier, univariate Cox, and multivariate Cox analysis. The correlations between
abundance of each TIC and each prognostic gene were calculated in TIMER and were visual-
ized via the "canvasXpress" R package. P-value < 0.05 was considered statistically significant.
Results
Clinical characteristics
The present research’s flowchart is shown in Fig 1. 80 UM cases from TCGA-UVM were
taken as the training cohort. The dataset GSE22138 with 63 UM patients was used as the vali-
dation cohort. The detailed clinical characteristics of both cohorts were summarized in
Table 1.
Intersection DEGs based on immune and stromal scores
For identifying the DEGs among immune and stromal scores, cases in the training cohort
were divided into groups of high and low scores according to their scores based on the median,
and the DEG analysis was performed using the "limma" R package. Fig 2A shows a heatmap of
1235 DEGs between immune score groups. Fig 2B displays a heatmap consisting of 1641
DEGs between stromal score groups. Via integrated bioinformatics analysis, we identified 873
intersection-up-regulated DEGs (Fig 2C) and 86 intersection-down-regulated DEGs (Fig 2D).
Our subsequent research focused on these 959 intersection DEGs (S2 Table). As shown in Fig
3A, the enriched GO terms in the intersection DEGs were mainly related to lymphocyte activa-
tion, cytokine-mediated signaling pathway, cytokine production regulation, adaptive immune
response, and leukocyte migration. And the KEGG terms were mostly focused on Cytokine-
cytokine receptor interaction, Hematopoietic cell lineage, Osteoclast differentiation, T cell
receptor signaling pathway, and Natural killer cell mediated cytotoxicity (Fig 3B).
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Identification and validation of the potential prognostic genes
Kaplan-Meier and univariate Cox regression analysis were performed on 80 UM patients in
the training cohort to assess the prognostic relationship between the 959 intersection DEGs
and overall survival. 537 genes were extracted from the Kaplan-Meier analysis, while 601
genes were identified as significant in the Cox regression analysis. Taking together, 475
genes in the intersection of the two results are defined as genes with prognostic value for
subsequent analysis (S3 Table). Also, we put the 475 genes into the validation cohort for
validation using the same methods as that in the training cohort. 83 genes were found prog-
nosis value via Kaplan-Meier analysis, and 72 genes were seen holding capacity of predict-
ing the outcome by Cox regression analysis. Finally, 52 potential prognosis genes were
discovered (S4 Table).
Fig 1. Flow chart of the study. The study was carried out in TCGA-LUAD and GSE72094 cohorts. The potential
prognosis genes were obtained from training cohort and the validation cohort. Then the correlation analysis between
the potential genes and the status of chromosome 3 and 8q and tumor metastasis were performed for prognosis genes.
At last, the immune infiltration analysis was conducted. DEGs: differentially expressed genes; GO: Gene Ontology;
KEGG: Kyoto Encyclopedia of Genes and Genomes; TICs: tumor-infiltrating immune cells.
https://doi.org/10.1371/journal.pone.0242263.g001
Table 1. Clinical characteristics of patients involved in the study.
Characteristics Training cohort (TCGA-UVM, n = 80) Validation cohort (GSE22138, n = 63)
Age at diagnosis, years
<60 36 (45.00%) 28 (44.44%)
�60 44 (55.00%) 35 (55.56%)
unknown 0 (0.00%) 0 (0.00%)
Gender
Female 35 (43.75%) 24 (38.10%)
Male 45 (56.25%) 39 (61.90%)
unknown 0 (0.00%) 0 (0.00%)
Stage
I 0 (0.00%) NA
II 36 (45.00%) NA
III 40 (50.00%) NA
IV 4 (5.00%) NA
unknown 0 (0.00%) NA
T classification
T1 0 (0.00%) NA
T2 4 (5.00%) NA
T3 36 (45.00%) NA
T4 38 (47.50%) NA
unknown 2 (2.50%) NA
N classification
N0 76 (95.00%) NA
N1 0 (0.00%) NA
unknown 4 (5.00%) NA
M classification
M0 51 (91.25%) 28 (44.44%)
M1 4 (3.75%) 35 (55.56%)
unknown 25 (5.00%) 0 (0.00%)
https://doi.org/10.1371/journal.pone.0242263.t001
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Fig 2. Identification of the intersection DEGs among immune and stromal scores in UM. (A) Heatmap of the DEGs of immune scores of top half (high score) vs.
bottom half (low score). (Cutoff: |log2(fold-change) |> 1, FDR< 0.05). (B) Heatmap of the DEGs of stromal scores of top half (high score) vs. bottom half (low score).
(Cutoff: |log2(fold-change) |> 1, FDR< 0.05). (C, D) Venn diagrams showing the number of intersection-up-regulated DEGs (C) or intersection-down-regulated
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Screening prognostic genes from comparing the status of chromosome 3,
chromosome 8q, and metastasis to the potential prognostic genes
Furthermore, to find prognostic genes in UM, we performed correlation analyses to assess the
relationship between the 52 potential prognosis genes and the status of chromosome 3, chro-
mosome 8q, and metastasis in TCGA-UVM cohort. 5 genes locate in chromosome 3 or 8,
including ALDH1L1, locating in chromosome 3; GEM, MTUS1, RIMS2, SLCO5A1, locating
in chromosome 8 (S4 Table). Spearman test was used to assess the correlation between copy
chromosome numbers, metastasis and the potential prognosis genes. The results showed that
52 genes were significantly correlated with copy numbers of chromosome 3, 50 genes were sig-
nificantly correlated with copy numbers of chromosome 8q, and 22 genes were significantly
correlated with tumor metastasis. Combining the above three results, 21 genes in the intersec-
tion (0 genes locate in chromosome 3, while 3 genes, including GEM, MTUS1, and SLCO5A1
locate in chromosome 8), were identified as prognostic genes (Table 2). The Kaplan–Meier
curves and univariate Cox analysis of 21 genes in the training cohort (Fig 4) and the validation
cohort (Fig 5) were plotted.
Correlation of prognostic genes identified with the abundances of six kinds
of TICs
First, we examined the impacts of six immune cells on the prognosis of UM. Kaplan–Meier,
univariate Cox, and multivariate Cox methods were applied to determine whether each type of
immune cell can influence the UM prognosis. Kaplan–Meier curves indicated that CD8+ T
cell and Neutrophil hold the capacity to predict UM outcome (Fig 6A). In univariate Cox anal-
ysis results, CD8+ T cell and Neutrophil were found to have predictive ability (Fig 6B). As
shown from the multivariate Cox test, B cell, Neutrophil, and Dendritic cell owned the prog-
nostic power (Fig 6B). Based on the above results, we could see that only Neutrophil main-
tained a significant predictive value in all three tests. Neutrophil was acting as a potential
prognostic immune cell in UM microenvironment.
Next, we checked the correlation between each prognostic gene and each TIC in UM. As
shown in Fig 7, almost all prognostic genes (except PAPSS2) were related to Neutrophil infiltra-
tion. Among them, SERPINB9, EDNRB, RAPGEF3, HFE, RNF43, ZNF415, IL12RB2, MTUS1,
NEDD9, ZNF667, and AZGP1 were positively correlated with Neutrophil infiltration, while
WARS, GEM, RAB31, CALHM2, CA12, MYEOV, CELF2, SLCO5A1, and ISM1 were nega-
tively correlated with Neutrophil infiltration. Besides, we found significant correlations also
occurred in the relationship between prognostic genes (except IL12RB2 and NEDD9) and CD8
+ T Cell. Interestingly, the correlation here with CD8+ T Cell infiltration is opposite to that in
Neutrophil. As shown in Fig 7, SERPINB9, EDNRB, RAPGEF3, HFE, RNF43, ZNF415,
MTUS1, ZNF667, and AZGP1 were negatively correlated with CD8+ T Cell, and WARS, GEM,
RAB31, CALHM2, CA12, MYEOV, CELF2, SLCO5A1, ISM1, and PAPSS2 were positively cor-
related with CD8+ T Cell infiltration. In addition to the correlations found above, other correla-
tions only existed between HFE and B Cell, and between CA12 and Dendritic Cell.
Overall, the analysis results showed that Neutrophil had the potential prognostic ability,
and almost every prognostic gene we had identified was correlated with the infiltration of Neu-
trophil and CD8+ T Cell.
DEGs (D) in stromal and immune score groups. Heatmaps were drawn based on the average method and correlation distance measurement method. Genes with higher
expression are shown in red, lower expression are shown in blue, genes with same expression level are in white. DEGs: differentially expressed genes; UM: uveal
melanoma; FDR: false discovery rate.
https://doi.org/10.1371/journal.pone.0242263.g002
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Fig 3. Bar graph of enriched GO (A) and KEGG (B) terms across the intersection DEGs in UM, colored by p-values. GO: Gene Ontology; KEGG: Kyoto Encyclopedia
of Genes and Genomes; DEGs: differentially expressed genes; UM: uveal melanoma.
https://doi.org/10.1371/journal.pone.0242263.g003
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Discussion
In the present study, we identified 21 UM prognostic genes from tumor microenvironment by
comprehensively analyzing the TCGA and GEO. By discovering the DEGs among tumor
microenvironment and investigating the potential prognosis of DEGs using Kaplan-Meier and
univariate Cox analyses in the training cohort, we obtained 475 genes that were pronounced
related to outcome. By applying these genes in the validation cohort screened by Kaplan-Meier
and univariate Cox analyses, 52 genes were validated holding potential prognostic value. What
is more important, we compared these 52 genes to the status of chromosome 3, chromosome
8q, and tumor metastasis, to get prognostic genes. Finally, 21 genes were identified as progno-
sis genes in our study. To clarify the relationship between these prognostic genes and immune
infiltration, we conducted an immune infiltration analysis with the 21 genes and 6 main TICs,
finding that the correlation between Neutrophil and 21 genes potentially acted as one of the
factors that contribute to the prognosis capacity of the 21 genes. On the “road” to find the
prognostic genes of UM, we are the first to combine tumor microenvironment scores and dou-
ble screening (Kaplan-Meier and univariate Cox methods) for training and introduce chromo-
some copy number variation for gene screen. Such work we have done aimed to guide future
research in UM.
Cancer is not only a cluster of malignant cells but also a complex "rogue" organ. Many
other cells are recruited into these organs and may be destroyed by transformed cells. The
interaction between malignant and non-transformed cells creates the tumor microenviron-
ment [27]. The presence of immune cells infiltrating in and around tumors and their relation-
ship with clinical outcomes have led to the hypothesis that the immune microenvironment is
an important prognostic factor for cancer [28, 29]. Tumor-infiltrating immune cells have been
Table 2. 21 prognostic genes identified in this study.
Gene chromosome 3 chromosome 8q metastasis Genomic location (GRCh38/hg38)
R P-value R P-value R P-value
SERPINB9 0.641 1.49E-10 -0.334 2.46E-03 -0.362 6.67E-03 chr6:2,887,265–2,903,312
EDNRB 0.790 3.00E-18 -0.467 1.25E-05 -0.326 1.50E-02 chr13:77,895,481–77,975,529
RAPGEF3 0.613 1.48E-09 -0.520 7.71E-07 -0.313 1.99E-02 chr12:47,734,363–47,771,040
HFE 0.668 1.32E-11 -0.656 3.90E-11 -0.304 2.39E-02 chr6:26,087,281–26,098,343
RNF43 0.697 6.66E-13 -0.444 3.69E-05 -0.300 2.61E-02 chr17:58,352,500–58,417,620
ZNF415 0.619 9.47E-10 -0.513 1.17E-06 -0.296 2.85E-02 chr19:53,107,879–53,133,077
IL12RB2 0.633 2.93E-10 -0.437 5.13E-05 -0.287 3.38E-02 chr1:67,307,351–67,397,090
MTUS1 0.682 3.17E-12 -0.652 5.79E-11 -0.287 3.38E-02 chr8:17,643,794–17,801,220
NEDD9 0.703 3.68E-13 -0.350 1.45E-03 -0.278 4.00E-02 chr6:11,183,298–11,382,348
ZNF667 0.628 4.33E-10 -0.521 7.06E-07 -0.278 4.00E-02 chr19:56,438,512–56,478,065
AZGP1 0.661 2.47E-11 -0.526 5.30E-07 -0.269 4.70E-02 chr7:99,966,720–99,976,112
WARS -0.677 5.25E-12 0.562 5.81E-08 0.269 4.70E-02 chr14:100,333,788–100,376,805
GEM -0.736 7.18E-15 0.595 5.92E-09 0.278 4.00E-02 chr8:94,249,253–94,262,350
RAB31 -0.705 2.80E-13 0.572 3.02E-08 0.282 3.68E-02 chr18:9,708,231–9,862,556
CALHM2 -0.764 1.65E-16 0.580 1.78E-08 0.296 2.85E-02 chr10:103,446,785–103,452,405
CA12 -0.559 6.90E-08 0.467 1.25E-05 0.300 2.61E-02 chr15:63,321,378–63,382,110
MYEOV -0.720 5.29E-14 0.577 2.15E-08 0.300 2.61E-02 chr11:69,294,138–69,367,726
CELF2 -0.709 1.96E-13 0.446 3.33E-05 0.318 1.82E-02 chr10:10,798,397–11,336,675
SLCO5A1 -0.738 5.57E-15 0.517 9.13E-07 0.331 1.36E-02 chr8:69,667,046–69,835,064
ISM1 -0.742 3.40E-15 0.581 1.55E-08 0.340 1.12E-02 chr20:13,221,274–13,300,651
PAPSS2 -0.618 9.99E-10 0.551 1.16E-07 0.406 2.12E-03 chr10:87,659,613–87,747,705
https://doi.org/10.1371/journal.pone.0242263.t002
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reported to correlate with clinical prognosis in various tumors like hepatocellular carcinoma
[30], colorectal cancer [31], gastric cancer [32]. The eye is an immune-privileged site, but
inflammation can exist in the established ocular tumor microenvironment [33, 34]. One recent
study has demonstrated that loss of BAP1 expression is strongly associated with immune mod-
ulation of the microenvironment, and it makes an impact on the immunotherapy of UM [35].
Furthermore, Narasimhaiah et al. found that immune cell infiltration was associated with
poorer outcomes in the intermediate-risk group and increased in the high-risk group, indicat-
ing that immune infiltration may be a promising biomarker repository for better-personalized
management of UM [10]. Our research on genes involved in the microenvironment of UM
provides an opportunity for the development of therapeutic agents or gene targets.
Studies showed that chromosome aberrations and gene mutations in UM are closely related
to clinical results. The loss of a chromosome 3 in UM is associated with an increased risk of
metastasis and poor prognosis [17, 20]. Previous studies have shown that besides chromosome
3, the increase in chromosome 8q is also related to poor survival prognosis [36–39]. Moreover,
metastasis is a strong predictor of the bad outcome. Only a fraction of patients with UM metas-
tasis survive [24]. Another report demonstrated that up to 50% of patients diagnosed with
uveal melanoma would die of metastasis after treatment of the tumor [24]. To make our
research more robust, we performed the Spearman test to assess the correlation between the
above-mentioned influential factors and the expression level of potential prognosis genes
obtained from the validation cohort to further screen prognostic genes in this study (Table 2).
In addition to chromosome 3 and 8q, other chromosomal abnormalities have been shown to
correlate with poor prognosis and these include 6q loss, lack of 6p gain, 1p loss, and 16q loss
[17–21]. Among the 21 prognostic genes found in this study, 7 genes (SERPINB9, HFE,
IL12RB2, MTUS1, NEDD9, GEM, and SLCO5A1) were located in the chromosomes as men-
tioned above (Table 2). These 7 genes potentially affect the chromosome variation, leading to
the occurrence and development of UM, but how they affect the UM is still unknown and
needs to be ascertained.
Specifically, our study identified 21 prognostic genes in UM. SERPINB9, EDNRB, RAP-
GEF3, HFE, RNF43, ZNF415, IL12RB2, MTUS1, NEDD9, ZNF667, and AZGP1 indicated a
favorable prognosis, while, WARS, GEM, RAB31, CALHM2, CA12, MYEOV, CELF2,
SLCO5A1, ISM1, and PAPSS2 suggested a poor outcome. EDNRB is a 7-span transmembrane
G-protein coupled receptor, and since membrane-located receptors constitute approximately
45% of all therapeutic drug targets [40]. A study showed that EDNRB expression is reduced in
large primary UM and small cell lung cancer with high metastatic genotype and phenotype.
The decreased expression of EDNRB in large primary UM is related to early clinical metastasis
and short survival [41]. WARS is a member of the aminoacyl-tRNA synthase family [42], also
known as TRPRS, WRS, which is a potential prognostic marker of metastasis [43]. WARS has
been found to be unbalanced in a variety of cancers (such as oral cancer, ovarian cancer, pan-
creatic cancer, colorectal cancer, etc.) [44–49]. A recent study showed that the expression of
WARS is up-regulated in UM cells and is related to the poor prognosis of UM patients. WARS
may partially promote the growth of UM cells by activating the PI3K/AKT signaling pathway,
thereby accelerating tumor development [44]. In addition to EDNRB and WARS, the remain-
ing 19 genes showing evidence interacting in the progress of various types of cancer [50–68],
but left few traces showing the connection with UM prognosis in the previous research.
Fig 4. Kaplan–Meier curves and univariate Cox analysis of 21 genes in the training cohort. (A) The Kaplan–Meier
curves of 21 genes in the training cohort. P-value was examined in the Log rank test. (B) The univariate Cox analysis of
21 genes in the training cohort. P-value< 0.01 is considered statistically significant. 95% CI: 95% Confidence Interval.
https://doi.org/10.1371/journal.pone.0242263.g004
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Besides our findings, LAG3 was defined as a potential candidate for immune checkpoint
blockade in patients with high risk UM in a recent study [69]. LAG3 is expressed on natural
killer cells, B cells, and dendritic cells. In addition, it is also expressed on the cell membrane of
tumor-infiltrating lymphocytes, activated CD4 + and CD8 + T cells, and regulatory T cells
[70]. LAG3 may be a very promising immune checkpoint. It is a co-inhibitory receptor that
suppresses T cell activation and cytokine secretion, thus ensuring immune homeostasis [71].
Targeted LAG3 immunotherapy is moving forward in active clinical trials, and the combined
immunotherapy of anti-LAG3 and anti-PD-1 has shown exciting effects in combating PD-1
resistance [70].
The immune infiltration analysis showed that Neutrophil infiltration had the most potential
prognostic capacity among 6 kinds of TICs in UM, and almost all the 21 genes identified were
correlated with Neutrophil infiltration. This finding indicated that the significant correlation
between Neutrophil and 21 genes potentially acted as one of the factors that contribute to the
prognosis capacity of the 21 genes. The analysis also found almost every prognostic gene corre-
lating with CD8+ T cell. However, CD8+ T cell did not show prognostic ability in UM based
on our analysis. The tumor-promoting effects of neutrophils are mediated by different mecha-
nisms. Neutrophils play an important role in angiogenesis by expression of matrix metallo-
proteases, such as MMP9 [72, 73]. Besides, neutrophils inhibit the anti-tumor CD8 + T cell
response by degranulation of granular constituents, production of ROS and release of arginase,
and expression of PD-L1 [74]. It has recently been shown that in a mouse model of breast
Fig 5. Kaplan–Meier curves and univariate Cox analysis of 21 genes in the validation cohort. (A) The Kaplan–
Meier curves of 21 genes in the validation cohort. P-value was examined in the Log rank test. (B) The univariate Cox
analysis of 21 genes in the validation cohort. P-value< 0.01 is considered statistically significant. 95% CI: 95%
Confidence Interval.
https://doi.org/10.1371/journal.pone.0242263.g005
Fig 6. Identification of the prognostic value of each TIC based on the 6 TICs infiltration volume and survival data. (A) Kaplan–Meier survival curves of 6 TICs in
UM. (B) Univariate and multivariate Cox analysis based on each of the 6 TICs infiltration volume and overall survival. All p-values were calculated using Cox regression
hazards analysis. The p-value in bold represents statistical significance (p-value< 0.05). TICs: tumor-infiltrating immune cells; UM: uveal melanoma.
https://doi.org/10.1371/journal.pone.0242263.g006
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Fig 7. Correlation analysis between 21 prognostic genes and 6 TICs in UM. The illustration is on the right. The
larger the circle, the smaller the p-value and the more significant the correlation. A circle with a black edge represents
statistical significance (p-value< 0.05). R: correlation coefficient; TICs: tumor-infiltrating immune cells; UM: uveal
melanoma.
https://doi.org/10.1371/journal.pone.0242263.g007
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cancer, neutrophils inhibit the anti-tumor T cell response and play a key role in tumor metas-
tasis [75]. However, how CD8 + T cells interplay with 21 genes and whether or how their rela-
tionship affects the prognosis of UM remains to be determined.
DecisionDx-UM is a prognostic test that determines the metastatic risk associated with UM
[76]. Specifically, the assay determines the activity or "expression" of 15 genes, which indicate a
patient’s individual risk, or class. According to the report of the Collaborative Eye Oncology
Group (COOG), the DecisionDx-UM GEP test is an accurate prospectively validated molecu-
lar classifier whose results are highly correlated with metastatic potential [77, 78]. In a prospec-
tive multicenter study, Plasseraud and colleagues demonstrated that the DecisionDx-UM
could accurately predict the risk of metastasis in patients with UM [79].
Our research also has some limitations. This study is to find immune related biomarkers,
which could give insight into immune modulation and potential clinical targets. However,
compared with the seminal work of DecisionDx-UM performance on UM prognosis predict-
ing, the presented work may remain limit. Although TCGA-UVM is a cohort that is currently
recognized by most scholars, the data in it are from large uveal melanoma treated with enucle-
ation. Similarly, the GSE22138 cohort, which was published online on the GEO database plat-
form, and its academic recognition is also undoubted. Still, most of the data in it came from
large eye tumors. Such sample distribution in these two cohorts may not be consistent with the
clinical population. Therefore, our research may have a selection bias for database selection. It
is unclear how many of those markers would actually hold up in a truly prospective study not
relying on sequencing data from very large tumors. Our 21 prognosis genes came from retro-
spective data, and more prospective data were needed to prove its clinical utility. In addition,
there is currently no wet experimental data explaining the relationship between these 21 genes
and their mechanism in UM samples. Therefore, between the 21 genes and the prognosis of
UM, more effort is needed to clarify the potential relationship.
Conclusion
In conclusion, our research defined 21 prognosis genes in UM. It is a comprehensive analysis
of the TCGA and the GEO database. These genes were related to the prognosis of UM and can
accurately identify the outcome of patients. Notably, we adopted the comparison with the sta-
tus of chromosomes 3 and 8q, and tumor metastasis to further screen prognosis genes. The
immune infiltrating analysis revealed that the 21 genes had close interactions with Neutrophil,
which may advance new therapies for UM treatment.
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